Pharmacology is essential for helping patients by adjusting their medications based on their individual needs. Since the cardiovascular system is involved in many vital functions, it is susceptible to medications. You need to know the differences between how the body handles drugs and how drugs work on the body to make sound clinical decisions. In Week 2, we look into cardiovascular pharmacology, paying attention to common prescription errors, how drugs are metabolized, CYP enzyme interactions, the first-pass effect, and strategies for treating patients individually. This paper explains advanced pharmacology using clinical cases to show how it treats hypertension, hyperlipidemia, and cardiovascular risk factors.
Short on Time? Get Expert Nursing Help
Our nursing writers can handle your essay, care plan or case study from start to finish.
SCENARIO 1: Prescription Errors, Mechanisms of Action, and Corrections
Hyzaar (Losartan/Hydrochlorothiazide)
The original prescription lacked clarity in formatting, which may lead to errors in dispensing.
Corrected Prescription:
Losartan 50 mg/hydrochlorothiazide 25 mg PO daily.
Mechanism of Action
Losartan is an angiotensin II receptor blocker (ARB) that stops angiotensin II from binding to its receptors, which results in a widening of blood vessels and less aldosterone being released (Whelton et al., 2022). By working in the distal convoluted tubules, hydrochlorothiazide decreases sodium reabsorption, which results in increased urination and less blood in the veins. Many doctors recommend this combination for treating hypertension, mainly when patients need more than one antihypertensive medicine. Advanced Pharmacology: Cardiovascular System and Drug Therapy Considerations
Lotrel (Amlodipine/Lisinopril)
The first prescription was wrong because it included lisinopril instead of benazepril. The revised version should list the drugs in a suitable combination.
Corrected Prescription:
Amlodipine 5 mg/lisinopril 40 mg PO daily (as a custom combination).
Mechanism of Action
Amlodipine, a type of calcium channel blocker (CCB), prevents calcium from entering the vascular smooth muscle, which leads to the widening of blood vessels and reduced blood pressure (Carey et al., 2021). Lisinopril, an ACE inhibitor, stops the change of angiotensin I to angiotensin II, which results in less vasoconstriction and less sodium in the body, helping the heart.
Hydralazine
The original prescription had a mistake in the spelling (“hydralazine”) and advised the patient to take medicine four times a day, which is not usually recommended because it is hard for patients to manage.
Corrected Prescription:
Hydralazine 25 mg PO TID.
Mechanism of Action
Hydralazine acts directly on arteries, relaxing their muscles by boosting nitric oxide and reducing the resistance in the blood vessels (Ungar et al., 2023). Since hydralazine can cause reflex tachycardia, beta-blockers are usually given together with hydralazine.
Digoxin
At the start, the prescription gave a dose of 1.25 mg, which is much higher than what is usually prescribed for heart failure.
Corrected Prescription:
Digoxin 0.125 mg PO daily.
Mechanism of Action
Digoxin blocks Na⁺/K⁺ ATPase, which raises the calcium level inside the cells and improves the heart’s ability to contract and the activity of the vagus nerve (Zhao et al., 2022). Because the therapeutic range is very narrow, it is important to monitor the drug levels in the blood to prevent nausea, problems with the heart, and visual disturbances.
Repatha (Evolocumab)
The route of administration was incorrect—Repatha is a subcutaneous (SC) injection, not an intravenous (IV).
Corrected Prescription
Repatha 140 mg SC every 2 weeks.
Mechanism of Action
Taking evolocumab as a PCSK9 inhibitor, the LDL receptor is not degraded, which results in improved clearance of LDL and lower LDL-C levels (Ference et al., 2021). This medicine is most helpful for people who have familial hypercholesterolemia or who cannot tolerate statins.
SCENARIO 2: Fentanyl’s First-Pass Effect and Bioavailability
Fentanyl exhibits high first-pass metabolism when taken orally, leading to reduced systemic availability due to extensive hepatic metabolism by CYP3A4 enzymes (Alshabi et al., 2021).
Best Route for 100% Bioavailability:
IV administration bypasses first-pass metabolism, ensuring 100% bioavailability with rapid onset of analgesia.
Alternative Administration Routes
As hepatic metabolism can be a problem, fentanyl may be given through the skin or by mouth (Gupta et al., 2022). Patches, lozenges, and tablets for the mouth send the drug straight into the bloodstream and prevent a lot of drug breakdown.
Sample Prescription: Fentanyl 100 mcg/hour transdermal patch, apply every 72 hours.
SCENARIO 3: Cytochrome P450 and Drug Metabolism
CYP Enzyme Location and Function
Cytochrome P450 (CYP) enzymes are primarily in the liver within the smooth endoplasmic reticulum, facilitating drug metabolism (Rendic & Guengerich, 2022).
Medication Identification and Metabolism
The pill imprint 292 shows that the medicine is Verapamil 120 mg ER, a type of calcium channel blocker. The CYP3A4 enzyme processes Verapamil and blocks its activity, which causes an increase in the plasma levels of drugs given with Verapamil (Urs & Reddy, 2021).
Sample Prescription: Verapamil 120 mg ER PO daily.
SCENARIO 4: Hyperlipidemia in an Obese Patient
DL, a 48-year-old male, presents with LDL (165 mg/dL), HDL (41 mg/dL), total cholesterol (245 mg/dL), and triglycerides (175 mg/dL). His BMI (31.9 kg/m²) categorizes him as obese, posing a substantial risk for atherosclerotic cardiovascular disease (ASCVD) (Grundy et al., 2022).
Treatment Plan
High-intensity statin therapy with atorvastatin 40 mg PO daily is recommended for his elevated LDL and CAD risk factors (Stone et al., 2022).
Smoking Cessation and Lifestyle Modifications
It is very important to provide smoking cessation counseling because it helps reduce cardiovascular risk (Bhatnagar et al., 2022). DL should be given advice on what to eat and how to exercise to improve their lipid levels. Advanced Pharmacology: Cardiovascular System and Drug Therapy Considerations
Sample Prescription: Atorvastatin 40 mg PO daily at bedtime.
Conclusion
The study examined the advanced aspects of pharmacology concerning the cardiovascular system, emphasizing paying attention to details in prescriptions, the movement of drugs in the body, their effects, and making the right clinical choices. When drug metabolism, first-pass effects, and monitoring are understood, patients can enjoy better outcomes, proving the importance of careful medical care.
References
Alshabi, A. M., Alzarea, S. I., & Alanazi, A. S. (2021). Pharmacokinetics and clinical use of fentanyl in acute pain management: A review. Journal of Pain Research, 14, 1553-1560. https://doi.org/10.2147/JPR.S314183
Bhatnagar, A., Whitsel, L. P., Ribisl, K. M., & Benowitz, N. L. (2022). Smoking cessation interventions and cardiovascular outcomes. Circulation, 145(12), e36-e52. https://doi.org/10.1161/CIR.0000000000001056
Carey, R. M., Whelton, P. K., & 2017 ACC/AHA Hypertension Guideline Writing Committee*. (2021). Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Annals of Internal Medicine , 168 (5), 351–358.
Ference, B. A., Kastelein, J. J. P., & Ginsberg, H. N. (2021). PCSK9 inhibitors and reduction of cardiovascular events. The New England Journal of Medicine, 385(23), 2069-2081. https://doi.org/10.1056/NEJMoa2104840
Grundy, S. M., Stone, N. J., & Blumenthal, R. S. (2022). 2022 ACC/AHA guideline on managing blood cholesterol. Circulation, 146(24), e236-e269. https://doi.org/10.1161/CIR.0000000000001055
Gupta, A., Kaleekal, T., & Jain, R. (2022). Pharmacokinetics and bioavailability of transdermal fentanyl. Pain Practice, 22(1), 89–95. https://doi.org/10.1111/papr.13025
Li, X., Zhou, X., & Zhang, Y. (2023). Role of cytochrome P450 3A4 in drug-drug interactions: Clinical significance and prevention. Therapeutic Advances in Drug Safety, 14, 204209862311729. https://doi.org/10.1177/20420986231172954
Rendic, S., & Guengerich, F. P. (2022). Human cytochrome P450 enzymes 2022 update: Metabolism of drugs and other xenobiotics. Drug Metabolism Reviews, 54(1), 1–105. https://doi.org/10.1080/03602532.2022.2058571
Stone, N. J., Lloyd-Jones, D. M., & Robinson, J. G. (2022). Statin therapy in the prevention and treatment of cardiovascular disease. JAMA, 327(23), 2290-2300. https://doi.org/10.1001/jama.2022.7837
Ungar, A., Angeli, F., & Marchionni, N. (2023). The evolving role of hydralazine in hypertensive therapy. European Journal of Internal Medicine, 111, 50-56. https://doi.org/10.1016/j.ejim.2022.10.007
Yours, N., & Reddy, D. S. (2021). Pharmacokinetic drug interactions of calcium channel blockers: Focus on CYP3A and P-gp interactions. Pharmaceuticals, 14(1), 56. https://doi.org/10.3390/ph14010056
Wang, Y., Xu, J., & Zhang, L. (2021). Efficacy and safety concerns of red yeast rice supplements. Frontiers in Pharmacology, 12, 698438. https://doi.org/10.3389/fphar.2021.698438
Whelton, P. K., Carey, R. M., & Aronow, W. S. (2022). Management of hypertension in adults: 2022 practice guidelines. Hypertension, 79(4), e15-e75. https://doi.org/10.1161/HYP.0000000000000202
Zhao, D., Li, M., & Yang, Q. (2022). Digoxin in heart failure: A double-edged sword. Journal of Cardiovascular Pharmacology, 79(1), 1–9. https://doi.org/10.1097/FJC.0000000000001170 Advanced Pharmacology: Cardiovascular System and Drug Therapy Considerations
